Invivo Therapeutics Holdings Corp (OTC:NVIV), alliance with the Miami Project to Cure Paralysis will be featured at the Buoniconti Fund to Cure Paralysis 26th Annual Great Sports Legends Dinner fundraising event, to be held Monday evening, September 26 at the Waldorf Astoria New York Hotel. InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. Among the topics to be covered under the agreement is InVivo’s tissue engineering technology in conjunction with the Miami Project’s Schwann cells. Dr. Robert S. Langer, co-founder of InVivo Therapeutics Holdings Corp. was named as one of Thomson Reuters annual top tips to win the 2011 Nobel Prize for Medicine for his work in tissue engineering. Awarded annually in early October, the foretelling was done by Nobel prediction expert David Pendlebury.
Frank Reynolds, InVivo’s Chief Executive Officer quotes, “We look forward to the results of our preclinical work with the Miami Project, and are hopeful that the combination of the scaffold and Schwann cells will improve the therapeutic effect of both technologies, Our scaffold has shown excellent results in non-human primates and in a rodent contusion model treating paralysis following acute spinal cord injury. We remain on target to begin a 10-patient pilot study in acute spinal cord injury in 2012.”
Shares of NVIV closed at $0.68 on Thursday. The stock has 30-Day average volume of 29K shares.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.